Michigan Supreme Court allows state probe into Lilly insulin pricing
The Michigan Supreme Court rejected Eli Lilly's effort to block a state investigation into its insulin pricing. The court's ruling allows Michigan Attorney General Dana Nessel to proceed with a probe under the state's consumer protection laws, examining whether the company's pricing practices constitute unfair or deceptive conduct. This state-level action adds to the ongoing national scrutiny of drug pricing and could influence similar investigations in other states, even as federal legislation on insulin costs remains stalled. The ruling does not determine liability but affirms the state's authority to investigate.